Jci_page_head_homepage_01 Jci_page_head_homepage_02
Jason M. Butler, Steven M. Guthrie, Mehmet Koc, Aqeela Afzal, Sergio Caballero, H. Logan Brooks, Robert N. Mames, Mark S. Segal, Maria B. Grant, Edward W. Scott
Published in Volume 115, Issue 1
J Clin Invest. 2005; 115(1):86–93 doi:10.1172/JCI22869
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 2

SDF-1 concentrations in the vitreous of human patients after treatment with triamcinolone. All patients were treated with at least 1 round of triamcinolone (4 mg) injections intravitreally. Vitreous samples were obtained 1 month after treatment. Human SDF-1–specific ELISAs were performed in triplicate on the vitreous samples. The results are presented according to the severity of the patients’ original disease. DME only, n = 30; DME + PDR, n = 20. The most fulminate stage of the disease is represented by patients with NVI (n = 4). Control vitreous samples (n = 8) were obtained from nondiabetic patients being treated for other ailments. All control samples were below the level of detection by ELISA (18 pg/ml SDF-1).